Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

Exclusion Criteria

• •DSM-IV criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, a psychotic disorder due to a general medical condition, psychosis NOS, delusional disorder, brief psychotic disorder, shared psychotic disorder, or a mood disorder (major depression or bipolar) with psychotic features assessed with the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-I/P) (First 1998)
• •DSM-IV diagnosis of any psychoactive substance dependence other than cannabis or nicotine
• •being in an environment with no access to cannabis (e.g., hospitalization, residential treatment, jail, ..) for more than one week during the past three months preceding study entry
• •serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain
• •use of medications that have an effect on monoamines (e.g., antidepressants
• •severe medical or physical illnesses
• •criteria of the National Cholesterol Education Program (NCEP) for a metabolic syndrome (Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001)
• •medical condition that requires treatment with a medication that has psychotropic effects
• •significant risk of suicidal or homicidal behavior
• •cognitive or language limitations, or any other factor that would preclude subjects providing informed consent or participating in study procedures
• •treatment with medications for addiction
• •treatment with medication having a risk of addiction (e.g., benzodiazepines, barbiturates)
• •history of treatment resistance to quetiapine ER
• •medical contraindications to quetiapine ER
• •hypersensitivity to quetiapine ER or any of its component
• •for women, pregnant, breastfeeding, or intention to become pregnant during the study timeframe